Nabulsi Nadia A, Naing Khatija W, Deng Huiwen, Cueto Jenilee, Asfaw Alemseged A, Hubbard Colin C, Zhou Jifang, Lee Inyoung, Mitra Debanjali, Calip Gregory S, Law Ernest H
Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL, USA.
Division of Health Policy and Administration, University of Illinois at Chicago, Chicago, IL, USA.
J Patient Exp. 2022 Jul 11;9:23743735221113058. doi: 10.1177/23743735221113058. eCollection 2022.
This study describes health-related quality of life (HRQoL) among older Medicare beneficiaries with hormone receptor-positive (HR+) early breast cancer (eBC). Women aged ≥65 years diagnosed with stage I-III HR+ eBC between 1997 and 2014 using the Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey Data Resource were included. HRQoL was measured using the Short Form Health Survey including physical/mental component summary (PCS/MCS) scores and subscales. Patient surveys ≤ 24 months post-diagnosis were matched to non-cancer controls. Mean differences in HRQoL were compared using analysis of covariance. Among 1880 HR+ eBC patients versus 5640 matched non-cancer controls, eBC patients surveyed ≤ 6 months post-diagnosis (n = 530) scored lower on component scores (PCS mean difference = 1.6 [95%CI: 0.6-2.6]; MCS mean difference = 2.0 [95%CI: 1.0-3.0]) and multiple subscales. Among women surveyed 19 to 24 months post-diagnosis (n = 402), mean differences in HRQoL were modest (PCS: 1.2 [95%CI: 0.1-2.4]; MCS: -1.5 [95%CI: -2.7 to -0.3]). Most differences in HRQoL following diagnosis of eBC did not indicate statistical significance or minimally important difference, emphasizing that preservation of HRQoL is an important and realistic goal among patients with eBC.
本研究描述了患有激素受体阳性(HR+)早期乳腺癌(eBC)的老年医疗保险受益人的健康相关生活质量(HRQoL)。纳入了1997年至2014年间使用监测、流行病学和最终结果医疗保险健康结果调查数据资源诊断为I-III期HR+ eBC的65岁及以上女性。使用包括身体/心理成分总结(PCS/MCS)评分和子量表的简短健康调查问卷来测量HRQoL。诊断后≤24个月的患者调查与非癌症对照组进行匹配。使用协方差分析比较HRQoL的平均差异。在1880例HR+ eBC患者与5640例匹配的非癌症对照组中,诊断后≤6个月接受调查的eBC患者(n = 530)在成分评分(PCS平均差异= 1.6 [95%CI:0.6 - 2.6];MCS平均差异= 2.0 [95%CI:1.0 - 3.0])和多个子量表上得分较低。在诊断后19至24个月接受调查的女性(n = 402)中,HRQoL的平均差异较小(PCS:1.2 [95%CI:0.1 - 2.4];MCS:-1.5 [95%CI:-2.7至-0.3])。eBC诊断后HRQoL的大多数差异未显示出统计学意义或最小重要差异,强调保留HRQoL是eBC患者的一个重要且现实的目标。